Harvard Bioscience (HBIO)
Builds research tools for preclinical and cellular-and-molecular science.
Something off on this page? Send us feedback.
Sells preclinical, cellular-and-molecular, and electrophysiology research tools. Its portfolio is being aligned around translational-science applications after an acquisition-led expansion of complementary technologies.
Preclinical, cellular-and-molecular, electrophysiology, and related research tools make up the portfolio. The business grew from Harvard Apparatus physiology equipment into a broader collection of life-science technologies through internal development and acquisitions. The collection reflects an acquisition-led evolution rather than a single product line.
A translational-science focus now guides the portfolio, innovation pipeline, and operating model. The company describes its role as a bridge from traditional research tools toward translational-medicine applications.
Recent operations have included restructuring, discontinuing certain non-strategic products, and manufacturing consolidation. Those changes shape the operating model alongside the portfolio transition.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Mar 13, 2026 | New Street | Target | Target: — | Target: $0.60 |
| Apr 9, 2025 | Keybanc | Downgrade | ||
| Apr 8, 2025 | Keybanc | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.5M · Total debt $44.2M · Total assets $76.3M · Shareholders' equity $7.4M
- Revenue
- $22.7M
- Operating income
- −$978.0K
- Net income
- −$2.9M
No dividends on record.
| Institutions | 29.73% | 1.35M shares | |
|---|---|---|---|
| 34 holders · as of Jun 30, 2026 | |||
| Insiders | 33.01% | 1.50M shares | |
| 9 holders · as of Jun 12, 2026 | |||
| Other | 37.26% | 1.70M shares | |
| remainder | |||
4.55M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
William Snider1Insiderdirector | 18.95% | 846,000 | filed Jun 11, 2026 |
Weber Capital Management LLC /AdvInstitution | 6.83% | 310,861 | as of Jun 30, 2026 |
Leviticus Partners LPInstitution | 6.45% | 293,676 | filed May 14, 2026 |
James W. GreenInsiderdirector | 5.39% | 245,257 | filed Aug 19, 2025 |
John D. DukeInsiderdirector, officer: Chief Executive Officer | 3.95% | 180,000 | filed Mar 23, 2026 |
- William Snider's transaction reports restate only vehicles that traded; the 2026 ownership statement (846.0K) plus the 16.6K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 16, 2026 | Mark T. Frost | officer: Chief Financial Officer | +5,000 | $5.00 |
| Mar 16, 2026 | William Snider | director | +12,525 | $4.99 |
| Mar 17, 2026 | William Snider | director | +8,475 | $4.85 |
| Mar 17, 2026 | Stephen J. Denelsky | director | +10,000 | $4.87 |
| Mar 16, 2026 | John D. Duke | director, officer: Chief Executive Officer | +5,000 | $5.01 |
- Revvity
Preclinical in vivo imaging and drug-development research tools
- Danaher
Cellular analysis, high-throughput screening, and microplate platforms
- Thermo Fisher Scientific
Life-science instruments, cell analysis, and molecular workflows
- Bio-Rad Laboratories
Life-science analysis tools for cell and molecular biology
- Agilent Technologies
Cell analysis, microplate automation, and research flow cytometry
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Harvard Bioscience | $8.06 | +0.75% | $36.1M | — | 44.8 | 0.4 | +11.1% |
| Revvity | $143.27 | −0.22% | $16.02B | 68.4 | 25.5 | 5.5 | −1.3% |
| Danaher | $221.98 | +2.84% | $151.67B | 38.3 | 25.1 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $659.17 | +0.06% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Bio-Rad Laboratories | $382.35 | +1.33% | $10.16B | 45.7 | 37.1 | 3.9 | −0.1% |
| Agilent Technologies | $166.28 | +2.68% | $45.75B | 31.9 | 25.3 | 6.2 | +8.1% |
| Median | 38.3 | 25.3 | 5.5 | +5.5% |